A bispecific antibody-drug conjugate doubled time to progression in HR+ breast cancer

Hormone-receptor-positive, HER2-negative breast cancer is the most common form of the disease. When it stops responding to hormone-blocking therapy and spreads, treatment usually moves to single-agent chemotherapy — effective for a while, but rarely for long. A phase 3 trial published in The Lancet on 26 October tested a new class of drug against that standard [s1].

What the drug is

Izalontamab brengitecan, written iza-bren in the trial report, is a bispecific antibody-drug conjugate. Two features set it apart from ordinary chemotherapy. First, it is bispecific: its antibody component is built to latch onto two different targets on cancer cells at once, EGFR and HER3, rather than one. Second, it is a conjugate: that antibody carries a chemotherapy payload and delivers it to the cells it binds, aiming to concentrate the toxic effect on the tumour [s1]. The design is meant to be more selective than chemotherapy that circulates through the whole body.

Targeting EGFR and HER3 together is a deliberate choice. Both are growth-signal receptors that breast cancers can lean on, and hitting two at once is meant to make it harder for the tumour to slip the drug by switching from one to the other. But in an antibody-drug conjugate, the antibody's main job is delivery — getting the chemotherapy payload to the cancer cell — so the two targets widen the range of cells the drug can reach rather than acting as two separate attacks.

PANKU-Breast01 asked a direct question: in people whose HR-positive, HER2-negative breast cancer had already been treated, does this targeted drug delay progression longer than the chemotherapy a doctor would otherwise reach for?

How the trial was built

PANKU-Breast01 was a randomised phase 3 trial conducted in China, registered as NCT06343948 [s1][s2]. From 560 people screened, 383 were randomly assigned and treated — 190 to iza-bren and 193 to chemotherapy; their median age was 54.0 years [s1].

The iza-bren group received the drug at 2.5 mg/kg intravenously on day 1 and day 8 of every three-week cycle [s1]. The control group received the treating physician's choice of single-agent chemotherapy: eribulin at 1.4 mg/m², vinorelbine at 25 mg/m², gemcitabine at 1000 mg/m², or oral capecitabine at 1000–1250 mg/m² twice daily on days 1–14 of each three-week cycle — all standard options for this setting [s1]. The primary endpoint was progression-free survival, judged by a blinded independent central review panel reading the scans by RECIST v1.1 without knowing which treatment a patient was on [s1].

What it found

The primary endpoint favoured iza-bren clearly. Median progression-free survival was 8.2 months with the antibody-drug conjugate against 4.0 months with chemotherapy, a hazard ratio for progression or death of 0.41 (95% CI 0.33–0.53; p<0.0001) [s1]. Over a median follow-up of 15.2 months, that is a doubling of the time before the cancer worsened [s1]. For a setting where each successive chemotherapy tends to hold the disease for a shorter stretch than the last, adding four months before progression is a clinically meaningful margin [s1].

The trade-off was toxicity. Grade 3 or higher treatment-related adverse events occurred in 85% of the iza-bren group versus 66% of the chemotherapy group [s1]. A notable share of that burden involved the blood: in the iza-bren arm, 73% of patients received platelet-elevating agents, 15% needed a platelet transfusion, and 10% a blood transfusion [s1]. There were two treatment-related deaths in the iza-bren arm [s1].

What is, and is not, established

What PANKU-Breast01 supports is that, in previously treated HR-positive, HER2-negative breast cancer, izalontamab brengitecan roughly doubled progression-free survival compared with standard single-agent chemotherapy [s1]. That is a substantial delay in progression for a common and hard-to-treat setting.

The qualifications are important. Overall survival — whether people actually lived longer — was immature at this analysis and not reported, so the key question of survival benefit is still open [s1]. The severe-side-effect rate was high, much of it affecting the blood and requiring transfusions and supportive drugs, which is a real cost to weigh against the delay in progression [s1]. The trial was conducted entirely in China, so how far the results generalise to other populations is not yet established [s1]. And iza-bren is investigational; these results describe a trial, not an approved treatment [s1].

Red flags: anyone on chemotherapy or an antibody-drug conjugate who develops a fever, unusual bruising or bleeding, severe fatigue, or breathlessness should contact their oncology team, as these can signal low blood counts or other serious effects. This article describes research and is not medical advice. Treatment choices in advanced breast cancer are for patients and their treating oncologists.